- Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
- Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
- Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
- Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
- Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
More ▼
Key statistics
As of last trade Verrica Pharmaceuticals Inc (VRCA:NMQ) traded at 9.06, -20.60% below its 52-week high of 11.41, set on May 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.10 |
---|---|
High | 9.16 |
Low | 8.84 |
Bid | 9.03 |
Offer | 9.09 |
Previous close | 9.05 |
Average volume | 352.70k |
---|---|
Shares outstanding | 42.42m |
Free float | 18.75m |
P/E (TTM) | -- |
Market cap | 383.90m USD |
EPS (TTM) | -1.75 USD |
Data delayed at least 15 minutes, as of May 23 2024 16:45 BST.
More ▼